- Home
- EYPT vs XPEL Comparison
EYPT vs XPEL Comparison
Compare EYPT & XPEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | XPEL |
|---|---|---|
| Founded | 1987 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Industrial Specialties |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2005 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EYPT | XPEL |
|---|---|---|
| Price | $14.67 | $47.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $31.80 | ★ $56.00 |
| AVG Volume (30 Days) | ★ 795.3K | 268.7K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.12 |
| EPS | N/A | ★ 1.85 |
| Revenue | $7,539,000.00 | ★ $476,200,000.00 |
| Revenue This Year | N/A | $12.64 |
| Revenue Next Year | $3,115.57 | $11.98 |
| P/E Ratio | ★ N/A | $24.97 |
| Revenue Growth | N/A | ★ 13.27 |
| 52 Week Low | $5.44 | $24.99 |
| 52 Week High | $19.11 | $55.91 |
Technical Indicators
Market Signals| Indicator | EYPT | XPEL |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 64.33 |
| Support Level | $14.50 | $35.79 |
| Resistance Level | $18.99 | $55.36 |
| Average True Range (ATR) | 0.66 | 1.77 |
| MACD | 0.25 | 0.67 |
| Stochastic Oscillator | 92.13 | 92.48 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services principally to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from Product, which includes Paint protection film and Window film. The company derives revenue from Service, which includes Software, Cutbank credits, and Installation labor. The majority of revenue is derived from the United States.